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Antimicrobial peptides (AMPs) are known best for their role in innate immunity 
against bacteria, viruses, parasites and fungi. However, not only are they showing 
increasing promise as potential antimicrobial drug candidates, recently, it has been 
reported that certain AMPs also show a cytotoxic effect against cancer cells. Their  
possible antitumor effect could make AMPs interesting candidate cancer biomarkers 
and a possible lead for new anticancer therapy. Due to their cyclic structure, detection 
and identification of AMPs is challenging, however, mass spectrometry (imaging; MSI) 
has been shown as a powerful tool for visualization and identification of (unknown) 
cyclic AMPs. In this chapter, we will discuss how mass spectrometry (imaging), com-
bined with the use of electron-transfer dissociation (ETD) as fragmentation technique, 
can be used as a reliable method to identify AMPs in their native cyclic state. Using 
this approach, we have previously detected and identified human neutrophil peptides 
(HNPs) as important AMPs in cancer, of which a detailed bacterial, viral and cancer-
related overview will be presented.
Keywords: human neutrophil peptide 1, 2 and 3 (HNP1-3), proteomics,  
mass spectrometry (imaging), immunomodulatory function, non-small cell lung 
cancer (NSCLC)
1. Introduction
In the beginning of last century, the first antimicrobial protein, lysozyme, was 
reported. A few years later, the best known antimicrobial compound, called penicillin, 
was discovered, which made research into natural antimicrobial proteins/peptides 
(AMPs) a very important research domain for therapeutic molecules that can be 
used against bacterial infections [1]. AMPs are naturally occurring small proteins (or 
peptides) in different organisms and are produced by many tissues and different cell 
types, acting as host defense molecules against bacteria, but with some also showing a 
fast antifungal, antiviral, antiparasitic and antitumor response [1–3].
The largest part of AMPs consists of antibacterial peptides with an inhibitory 
activity towards bacteria, both Gram-positive and Gram-negative [2]. Studies have 
revealed that AMPs exhibit an overall positive charge, allowing electrostatic inter-
actions with negatively charged phospholipid groups in the bacterial membrane. 
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By this attribute, pores can be formed by AMPs to disrupt the membrane integrity. 
Some AMPs are able to cross the lipid bilayer, followed by disruption of intracel-
lular functions such as blocking enzyme activity or inhibition of protein synthesis, 
both resulting in bacterial cell lysis [1]. For this reason, AMPs are often referred to 
‘natural antibiotics’.
AMP activity is not restricted to antimicrobial mechanisms, also AMP activity 
against parasites has been observed: a few AMPs are reported as antimalarial peptides 
and can possibly serve as new future drug targets against the malaria parasite. For 
example, cecropins have been shown to block the development of oocysts into sporozo-
ites, while dermaseptins (and some derivatives) have been found to be able to permea-
bilize the host cell membrane [4].
Furthermore, a subset of AMPs have shown antifungal characteristics against 
some fungi commonly found in food and agriculture, but also against the common 
Aspergillus and Candida albicans infections [2]. These antifungal peptides can inter-
act with fungal membranes to form pores, comparable to the AMP mechanism in 
bacteria, but they can also act by targeting the specific fungus cell wall or by acting 
as nucleic acid inhibitors through direct binding to nucleic acids [5]. A smaller part 
of AMPs also exhibit antiviral activity, by acting through different mechanisms. A 
first mechanism includes inhibition of virus attachment and cell membrane fusion. 
As an example, during the recent COVID-19 pandemic, the antiviral peptide (AVP) 
EK1C4 has been found to be very effective against S-mediated membrane fusion 
of the viral particles, thus inhibiting entry of the virus and thereby infection [6]. 
Another example of inhibition of virus attachment is demonstrated by derma-
septins, which possibly affect the lipid bilayer to alter the fusogenic properties of 
herpes simplex virus [7]. The virus for host cell infection can also be impeded by 
the direct action of certain AMPs, such as indolicidin, against enveloped virions, 
causing membrane instability by destruction of the virus envelope [8]. Combined, 
there is great potential for future therapeutic development of AVPs for both preven-
tion as treatment of infection [6]. A small number of AMPs are believed to be active 
as anticancer peptides (ACP). It has been suggested that they specifically target the 
membrane of cancer cells through interaction with phospholipids, mainly phos-
phatidylserine, present at the outer leaflet of the cancer cell membrane in higher 
amounts compared to normal cells. Moreover, the ACP LTX-315 has demonstrated 
both cytolytic and immunogenic properties towards cancer cells, as LTX-315 
induces tumor antigen and danger-associated molecular patterns (DAMPs) release, 
triggering an immune response towards the cancer cells [9].
AMPs are considered key components of the innate immune system, as shortly 
after an infection, these are promptly synthesized to neutralize a wide variety 
of pathogens, but through another mechanism compared to that of cytokines or 
phagocytes [10]. High concentrations of AMPs are usually required to exert an 
optimal pathogen killing activity, but in vivo, lower concentrations of AMPs are 
reported, in this case possibly acting as potent immune regulators, also leading to 
pathogen killing but rather through an indirect mechanism [11]. Besides permeabi-
lizing lipid membranes and bacterial walls, their primary role as antimicrobicidal 
agents, other targets of AMPs are thus reported. Recently, some AMPs are found 
to also modulate immune responses in vertebrates, through chemotactic activity, 
attraction, activation and differentiation of leukocytes and monocytes, influencing 
Toll-like receptor (TLR) recognition and through secretion of proinflammatory 
cytokines and chemokines, although their underlying mechanisms have not been 
fully characterized yet [1].
The best studied AMPs include the human defensins and cathelicidins and 
both have been shown to be chemotactic: β defensins (hBD) recruit (memory) T 
cells and immature dendritic cells through their chemotactic activity, suggesting 
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they promote cellular immune responses via interactions with the G protein-
coupled receptor CCR6 [11]. Another example of direct AMP chemotaxis 
includes cathelicidin LL-37, an AMP that has been proven to be chemotactic for 
neutrophils, monocytes and T cells, but not dendritic cells [11]. Additionally, an 
indirect chemotactic effect is possible by AMPs through inducing the release of 
pro-inflammatory cytokines and chemokines, to further refine and activate the 
innate, and eventually the adaptive, immune response [1, 11]. In synergy with 
particular immune mediators, LL-37 has been shown to enhance IL-6 and IL-10 
cytokine production, even as the production of macrophage chemoattractant 
proteins (MCP-1 and MCP-3) chemokines, resulting in an strengthened (innate) 
immune response [12]. Toll-like receptors (TLR) are key players in innate immu-
nity by recognizing microbe-associated molecular patterns (MAMPs). TLR 
activation leads to secretion of AMPs, but some AMPs, including cathelicidins, 
can modulate TLR-mediated inflammatory responses by strongly reducing 
LPS-induced TLR activation, mostly by inhibiting TLR4 [11, 13]. Lastly, AMPs, 
e.g. cathelicidins and β defensins, also exert a regenerative function by affecting 
wound healing, by stimulating migration, proliferation and tube formation of 
endothelial cells, through a cascade of activated pathways [11].
Overall, AMPs are important key players in host protection. Due to increasing 
antibiotic resistance, several AMPs have good potential therapeutic purposes, rang-
ing from antimicrobial, anti-inflammatory and immunomodulatory properties. Also 
co-administration of AMPs with existing therapies can have good clinical outcomes 
[14]. Recently, the ACP LTX-315 which has been described earlier, demonstrated in 
phase I human clinical studies to be an effective drug, due to its immunostimulatory 
effect resulting in tumor necrosis [9]. Currently, a phase I clinical trial for transder-
mally accessible tumors is ongoing to evaluate the efficacy of LTX-315 monotherapy 
or in combination with immune checkpoint inhibitor immunotherapy [9]. Still, 
some limitations for the therapeutic use of AMPs need to be resolved: high proteo-
lytic degradation of AMPs (i.e. susceptibility to proteases) is commonly observed, 
unpredicted toxicity is known to occur, chemical synthesis is costly and delivery of 
AMP targets to the site of infection can be very difficult [9, 14, 15]. As an example, 
LL-37 has proven to be very effective against Ebola virus infection, but its use as 
therapeutic molecule is limited as LL-37 is rapidly degraded and can lose its activity 
under certain conditions. These limitations were overcome with the design of an 
engineered LL-37 which prevents cell entry of the virus. The therapeutic outcome 
of these AMPs in animal models is ongoing, possibly combined with other small 
molecules that interfere with viral replication or together with virus-neutralizing 
antibodies [16].
AMPs mostly consist of 10 to 60 amino acids, including mainly basic and 
hydrophobic residues, resulting in positively charged molecules [1, 2]. They can be 
classified, based on their structure, into four categories; 1) linear extension struc-
ture, 2) α-helical AMPs, 3) AMPs consisting of β-strands stabilized by disulfide 
bonds and 4) both α-helical and β-sheet structures [2]. Due to their cationic proper-
ties, AMPs are easily detectable by mass spectrometric analysis. In addition, struc-
tural information of AMPs can be obtained by tandem mass spectrometry in which 
fragmentation spectra are obtained. Based upon this, the corresponding amino acid 
sequence can be determined and the precursor ion can be identified [17]. Even if the 
AMPs have a cyclic nature, due to their cysteine bond formation, mass spectrometry 
can be used as an identification tool, although a specific approach is needed [18–21]. 
The added benefit of using proteomic approaches to study AMPs is the fact that 
the majority of AMPs are post- or co-translational proteolytically processed from 
their large polyprotein precursor, resulting in the release of the active AMP. This 
is important as it allows for the identification of the active AMP in physiological 
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conditions. It overcomes the limitations of a genomics approach, as it can be 
complicated to predict the configuration of the exact active peptide from genomic 
sequences alone [22, 23]. In addition, due to their high positive charge, distribution 
of the AMP in a tissue can be analyzed using mass spectrometry imaging (MSI). 
MALDI MSI is a multiplexed analysis that allows the screening of hundreds of 
analytes simultaneously in a single tissue section without a priori knowledge of the 
present biomolecules [24–26]. Using MSI, a mass spectrum on every pixel of the 
tissue is recorded, representing all measured analytes by their mass-to-charge (m/z) 
ratio. The thousands of generated mass spectra can be combined. This thus provides 
not only structural information about the AMP, it also retains its spatial distribu-
tion and information on the relative abundance throughout the tissue [27]. This 
can overcome the limitation of antibody-related visualization with AMP-specific 
antibodies that are in some cases designed towards the non-active part of the AMP.
Overall, mass spectrometry (imaging) is an useful approach for the detection 
and identification of AMPs in their native and active form.
2.  Mass spectrometric detection and identification of human neutrophil 
peptides 1: 3 (HNP1-3)
2.1 Detection of AMPs in their native state
In the search for positive response patterns towards immune checkpoint inhibitors 
in non-small cell lung cancer (NSCLC) patients, we recently applied matrix-assisted 
laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) on pretreat-
ment tumor tissue biopsies. Since no prior knowledge of the molecules is required 
for MSI analysis, new unknown response patterns and biomarkers can be revealed. 
An additional advantage of using this visualization technique is that new, unknown 
biomolecules can be detected in their active and native state.
Using this approach, three peptides m/z 3369.5, m/z 3440.6 and m/z 3484.6 have 
found to be discriminative between a responding and a nonresponding NSCLC 
patient towards anti-PD-(L)1 immunotherapy, shown in Figure 1 [21].
2.2 Identification of (cyclic) AMPs
A major bottleneck of the direct analysis of tissues with MALDI-based MSI 
is the lack of a reliable identification of the visualized molecules, but it has been 
proven earlier that peptide/protein identification can be performed by using top-
down proteomics. This is a major challenge for identification of cyclic proteins or 
peptides, due to their intramolecular cysteine bridges.
Mass spectrometry followed by de novo sequencing has been described as a 
highly sensitive analytical technique to detect and characterize AMPs that are 
present in low concentrations within different species. Structural information of 
the intact AMP can be obtained by tandem mass spectrometry in which peptide 
ions are dissociated, resulting in a MS/MS spectrum from which the amino acid 
sequence can be derived. If required, the identification can be confirmed by 
comparing MS/MS spectra with those of the corresponding synthetic AMP [28]. 
Shotgun proteomics was performed on both short- and medium-sized antimicro-
bial peptides, generated by simulated gastrointestinal digestion, from yellowfin 
tuna samples. This has led to the identification of in total 572 sequences, followed 
by subjection to antimicrobial activity assays to unravel their AMP properties 
to evaluate their possible use as new future antimicrobial drugs [29]. In another 
study, antimicrobial proteins and peptides were extracted from different parts 
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of Charybdis pancration, a plant used in traditional medicine. These extracts are 
subsequently tested for their AMP activity against different antibiotic-resistant 
pathogenic strains. The extracted fraction that has displayed AMP activity, was 
further analyzed by using mass spectrometry leading to the discovery and identifi-
cation of seventeen novel peptides with AMP activity [30].
Identification of the cyclic peptides (shown in Figure 1) by collision-induced 
dissociation (either with CID or HCD), a routine approach in top-down peptidome 
analysis, is mostly not successful as fragmentation of the peptide backbone will not 
result in multiple fragments of different lengths. Rather, a long fragment with a 
mass close to the mass of the original parent (minus the loss of H2O) will be gener-
ated, irrespective of where the fragmentation occurred. Hence, these MS/MS spectra 
cannot be used to deduce a sequence tag that can be used to identify the peptide [31]. 
However, it has been shown that electron-transfer dissociation (ETD) can be used 
successfully for the identification of naturally occurring peptides [32], so, ETD has 
been applied as a fragmentation technique instead of HCD. Rather than generating 
fragments of the peptides by colliding them with an inert gas in CID, ETD induces 
fragmentation of large, multiply-charged cations by transferring electrons to them. 
ETD can be used effectively not only to break the peptide backbone (typically into 
C and Z ions), but also to reduce any cysteine bridges in the peptide [18–20]. This 
is nicely demonstrated in Figure 2B. An extract of the NSCLC tissue was prepared 
Figure 1. 
Average MALDI MSI spectra obtained with mass spectrometry imaging (MSI) analysis of whole formalin-
fixed paraffin-embedded (FFPE) tumor biopsies of NSCLC patients. (A) an example of a resulting average 
mass spectrum with three peptides m/z 3369.5, m/z 3440.6 and m/z 3484.6 of interest. (B) Average MSI spectra 
of 25 pretreatment tumor FFPE biopsies from NSCLC patients that received anti-PD-(L)1 immunotherapy. 
From this small patient cohort, nine patients received clinical benefit from the therapy (responders), from 
which seven patients showed expression of the three interesting peptides. The other 16 NSCLC patients did not 
derive any clinical benefit from immunotherapy treatment (non-responders), from which 14 show no (or very 
low) peptide expression. From the nonresponding patients, two NSCLC patients showed interesting peptide 
expression. Figure adapted from [21] with permission.
Antimicrobial Peptides
6
and analyzed with LC–MS/MS on a LTQ Velos Orbitrap (Thermo Fisher, Waltham, 
MA, USA) equipped with ETD. This type of instrument combines a dual stage linear 
ion trap with an orbitrap analyzer, an HCD cell and an ETD source. This allows for 
a very flexible use of different fragmentation techniques in the ion trap. In this case, 
the peptide is fragmented by using ETD and the resulting fragments were measured 
in the Orbitrap. The fragmentation of any of the three target peptides showed a 
neutral loss of 3 Da in each peptide (Figure 2B), corresponding to a reduction of 
three disulfide bridges between 6 cysteine residues [21].
The reduction of the disulfide bonds in effect turns the circular peptide into a 
linear one (Figure 2A and B). In a subsequent experiment, the resulting reduced 
and thus no longer circular peptide is selected and trapped in the ion trap for an 
additional fragmentation with CID (Figure 2C). In this way, multiple fragments are 
generated, measured this time in the ion trap, from which an amino acid sequence 
can be deduced. This leads to the identification of the peptide with mass 3440.6 
as human neutrophil peptide 1 (HNP1), presented in Figure 2D. The two other 
peptides of interest were analyzed in a similar way and identified as human neu-
trophil peptides 2 and 3. These three peptides have an almost identical amino acid 
sequence, only differing in the first amino acid residue [21].
To conclude, the combined approach of MSI and top-down proteomics using 
both ETD and CID has revealed human neutrophil peptide 1, 2 and 3, also known 
as neutrophil defensin 1, 2 and 3, as putative discriminative markers between 
a responding and a nonresponding NSCLC patient towards immunotherapy 
[21], highlighting a possible broader role for these AMPs than just a function as 
Figure 2. 
Mass spectra and annotated sequence of synthetic peptide corresponding for human neutrophil peptide 1 
(HNP1). A) Full MS spectrum of intact HNP1, in three different charge states. The five charged ion with m/z 
689.31 (mass 3441.6 Da) is selected for reduction of the three internal disulfide bridges with ETD;  
B) the resulting intact peptide m/z 1722.77 after reduction of three disulfide bridges. This reduced peptide is 
immediately selected for fragmentation with CID; C) the resulting fragmentation spectrum with c, y and z type 
ions; D) annotated sequence of human neutrophil peptide 1. Figure adapted from [21] with permission.
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antimicrobial peptides. Additionally, these results were verified with immuno-
histochemical (IHC) analyses on the same pretreatment biopsies with a defensin 
1/3 polyclonal antibody. In Figure 3, it is illustrated that IHC is feasible on FFPE 
tissue sections, previously MSI analyzed, without an apparent change in staining 
intensity [21].
This combined approach has been proven to be very useful in the detection and 
identification of interesting AMPs, especially in their native, processed form in a 
clinical context [21].
2.3 The biological activity of HNPs
The previously described observations were a starting point to explore the  
possible role of neutrophil defensins in cancer immunology.
Defensins, together with cathelicidins, are widely studied, as they were early 
recognized as important components of the antimicrobial mechanisms of leuko-
cytes. The defensins can be classified in human α-defensins, which are composed 
of β-strands, and human β-defensins, consisting of both α-helical and β-strands 
structures [33]. The sequences of these two defensin types include six cysteine 
residues and their cyclic structure is stabilized by formation of three intramolecular 
disulfide bonds, from which the cysteine bonding pattern makes a differentiation 
between α-defensins and β-defensins [33]. These cysteine residues are of major 
importance for their cationic antimicrobial characteristics [22]. A third class of 
defensins is also reported, called θ-defensins, and although mRNA expression of 
θ-defensins has been observed in humans, no functional AMPs from the θ-defensin 
family are reported to be produced in humans [22].
Figure 3. 
Distribution of human neutrophil peptides 1-3 in FFPE tissues after MSI and IHC analyses. A) Distribution of 
HNP1-3 obtained with MSI and the corresponding mass spectrum; B) validation of the presence of HNP1-3 in 
the same FFPE tissue, prior MSI analyzed, with IHC. The region indicated with the box in the MSI result was 




Currently, 31 β-defensins have been identified and are being studied. They are 
mainly expressed by epithelial cells and keratinocytes, but can also be secreted from 
macrophages, neutrophils and lymphocytes, suggesting a broader role in immune 
responses besides antimicrobial activity [22]. More importantly for this review 
part are the α-defensin family, more specifically the human neutrophil peptides 
1, 2 and 3 (HNP1-3), as previously described. As the name suggests, these AMPs 
are predominantly produced by neutrophils, but they have also been detected in 
macrophages, natural killer (NK) cells, immature monocyte-derived dendritic cells 
and some classes of T and B cells. The fourth α-defensin is also found in these cell 
types, while α-defensins 5 (HD5) and 6 (HD6) are secreted by intestinal Paneth 
cells, with the main function to provide intestinal host defense towards pathogens 
and to control and maintain homeostasis of the intestinal microbiome [22, 34]. HD5 
and HD6 deficiency is associated with Crohn’s disease, possibly due to the reduced 
antimicrobial defense capacity by lower HD5 and HD6 expression, leading to an 
altered microbiome composition [1, 35].
HNP1-3 have an almost identical amino acid sequence, only differing in a 
single amino acid residue, while this does not hold true for HNP4, HD5 and HD6 
(Figure 4), although all six α-defensins are characterized by the same cysteine 
residues [36]. HNP1 and HNP2 (the same is true for HNP2 and HNP3) are 
released from the same precursor, which is cleaved by a signal peptidase at posi-
tion 19 leaving a propeptide, which will be further processed by proteolysis in 
the developing granulocyte. The resulting mature peptide is then packaged into 
azurophilic granules of the neutrophils, with the HNPs representing more than 
30% of the total protein content in these granules [37]. Neutrophils are first-line 
defense immune cells against different pathogens and are directly recruited to sites 
of infection, followed by engulfment of the pathogen. Upon neutrophil activation, 
degranulation of azurophilic granules takes place, thus leading to abundant HNP 
release as a first-line of response to invading organisms [37–39]. These HNP1-3 
have been shown to have antibacterial, antiviral, anticancer and even immuno-
modulatory activities, which will be discussed further in more detail.
2.3.1 Antibacterial and antiviral activity of HNP1-3
HNP1-3 have a well described antibacterial activity, with demonstrated effectiv-
ity towards S. aureus, E. coli, P. aerugnosa and C. albicans through interaction of 
the positively charged HNPs with the anionic bacterial membrane. This can lead to 
different possible mechanisms, depending on the type of bacterium itself: the most 
common mechanism of HNPs includes destruction of the bacterial membrane, 
which is the case for P. aerugnosa and C. albicans. Lipid II, a bacterial wall precursor, 
is also a target for HNPs. Such example has been observed in S. aureus, in which 
HNP is responsible for lipid II restriction. In the case of E. coli, the disruption by 
HNP1 happens through intracellular targeting, by inhibiting the bacterium’s protein 
Figure 4. 
Alignment of the amino acid sequences of all 6 human α defensins. Conserved cysteine residues are presented in 
green and their corresponding cysteine bonding pattern is indicated.
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synthesis [40]. Furthermore, HNP1 has demonstrated direct activity towards 
Mycobacterium tuberculosis, the pathogen that can cause the infectious disease 
of tuberculosis, responsible for over a million deaths per year. The direct killing 
capacity of HNP1 includes permeabilization of the membrane, followed by pore 
formation [41]. HNP1 has even been considered as a lead compound in combat-
ing methicillin-resistant strains of Staphylococcus aureus (MRSA). When applied 
together with antibiotics, the HNPs show a synergistic effect towards different 
MRSA isolates, paving the way for a new therapeutic approach to overcome the 
increasing antibiotic resistance [42].
HNP1-3 have not only proven an effective response towards both Gram-positive 
and Gram-negative bacteria, but antiviral activity is also a well-known character-
istic of HNPs, including human immunodeficiency virus (HIV), human papilloma 
virus (HPV), herpes virus and influenza A virus (IAV) [2]. These HNPs have also 
been reported as anti-HIV peptides: high production of HNP1-3 by immature 
dendritic cells have a host protective role against progression of HIV-1, due to the 
direct HNP damage capability towards the virions, followed by the virion internal-
ization by the immature dendritic cell, leading to viral processing and presentation 
to HIV-specific CD4+ T cells [43]. In addition, HNP1-3 are identified in the female 
genital tract acting as host defense forming a natural barrier to HPV [44]. HNP1-3 
can inhibit herpes simplex virus (HSV) entry by directly binding to its target recep-
tor and these defensins even exhibit post entry antiviral activity, leading to reduced 
viral replication after HSV infection [22]. As a last example worth mentioning, 
these HNPs have an anti-IAV activity by direct interaction with the virus, leading 
to destabilization of the viral envelope and thus leading to virus inactivation. HNP1 
has also been suggested to bind the protein kinase C (PKC) receptor, in this way 
avoiding both IAV entry and replication [45, 46].
2.3.2 The role of HNP1-3 in cancer (immunity)
Already a direct antitumor effect has been described for human neutrophil 
peptides in a variety of tumor cells [47]. Furthermore, HNP1 has been reported as 
a potential prognostic biomarker in cancer [48–50]. In addition, the HNPs are sug-
gested to induce tumor necrosis [48, 49]. Although, despite the reported anticancer 
activity, defensins HD5 and HD6 are known markers of development and contribu-
tion to colorectal tumor growth [51].
In the same study in which we showed an association of the presence of HNPs 
and a response towards anti-PD-(L)1 immunotherapy in NSCLC, a possible immune 
stimulatory effect of HNPs towards lung cancer cells has been reported, while no 
such activity could be shown against non-tumoral cells [21]. In vitro data revealed 
that NSCLC cell proliferation is significantly reduced when cocultured with periph-
eral blood mononuclear cells (PBMC) from healthy donors. A conceivable explana-
tion for this observation is immune activation towards cancer cells, as an effect of 
addition of HNPs to the cancer cells was only observed in the presence of PBMC. 
Direct addition of HNPs to the three NSCLC cell lines in the absence of immune 
cells did not result in a significant decrease of tumor cell proliferation, and even an 
increase in tumor cell proliferation was observed in a certain case [21]. Furthermore, 
IFN-γ secretion was clearly increased in the PBMC and tumor cocultures after HNP-
treatment. Surprisingly, treatment of HNPs to PBMC from healthy donors in the 
absence of NSCLC cells did not result in an increase of IFN-γ release, indicating that 
HNPs contribute to activate the immune response, although not directly activating 
the immune cells. Also, non-tumoral cells remain insensitive to the action of HNPs. 
Neither was the effect explained by treatment with HNPs on the NSCLC tumor cells 
directly, as HNP treatment of only A549 cells did not result in IFN-γ release [21].
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Although earlier studies suggest a direct cytotoxic anticancer activity of the 
human neutrophil peptides [47–49], in this study, a possible immune–stimulatory 
effect of HNP1-3 towards lung cancer is suggested. The question raised by these 
findings is how these HNPs can act as immune-stimulatory effector, not directly 
on tumor cells nor on the immune cells, while leaving non-tumoral cells intact. A 
hypothesis is that α-defensins specifically target tumor cells by interaction with 
phosphatidylserine (PS) exposure. This interaction has been shown in a recent in 
vivo Drosophila model [52]. In general, cell membranes consist of PS that normally 
faces the inside of the cell due to the activity of phospholipid flippases. In apoptotic 
cells, PS can be exposed to the outer surface of the cells by loss of flippase activity 
and by activation of scramblases. In Drosophila, externalized PS serves as a marker 
for engulfment by macrophages leading to phagocytosis [53]. This mechanism 
seems to be preserved in human cells, including lung cancer cells [54], and cancer-
ous cells often increase exposure of the negatively charged PS on the outer leaflet 
of the cell membrane [55]. This would allow for the positively charged HNPs to 
interact with the negatively charged tumor cell surface PS, resulting in their cell 
death, while healthy cells remain insensitive to the HNP action, as PS is still present 
on the inner leaflet of the cell membrane by flippase activity [52].
PS exposure by the tumor cells have been driven in Drosophila through tumor 
necrosis factor (TNF) expression, while this exposure has not been observed on the 
normal cells [52, 54]. TNF-α concentrations have also been measured in the super-
natants of the PBMC and tumor cocultures treated with HNP1-3. For the NSCLC 
cell lines, an increase in TNF-α release was observed when the coculture was HNP 
treated, which was not observed for solely PBMC cultures nor for human bronchial 
epithelial cells BEAS-2B cocultured with PBMCs of three healthy donors [17]. This 
can possibly explain phosphatidylserine exposure on NSCLC cell lines, making the 
NSCLC cell membrane sensitive for interaction with the positively charged HNP 
to induce transmembrane permeability, a typical AMP characteristic [1]. In this 
way, tumor-associated antigens (TAAs) could be exposed to activate cell-mediated 
immunity by provoking an immunogenic response, resulting in a significant 
decrease in tumor cell proliferation [17, 21].
It is conceivable that HNPs play an immune-stimulatory role towards (lung) 
cancer cells. Due to their direct antimicrobial activity characteristics, HNPs are 
considered to be part of the innate immune response, just as neutrophils, their main 
cellular source, as approximately 9% of the neutrophil protein content includes 
HNPs [56]. Neutrophils have Jekyll and Hyde properties in relation to cancer, as 
they have been shown to elicit both antitumoral as protumoral activities [57, 58]. 
Tumor-associated neutrophils (TANs) have been linked with poor prognosis in 
late-stage tumorigenesis [58, 59]. Although, recent findings indicate antitumor 
properties of neutrophils in early-stage human tumors; neutrophils have been 
shown to present antigens, resulting in T cell interaction leading to a proper T cell 
activation and response. Furthermore, neutrophils are able to attract and activate 
these T cells through cytokine secretion [60]. It has also been proven that HNPs 
enhances adaptive immunity, however, their mechanisms remain largely unknown. 
Nevertheless, studies have shown that HNPs have immunostimulatory character-
istics through chemoattraction of naïve T cells [61], CD8+ T cells [37], monocytes 
[37], maturation and differentiation of immature dendritic cells [43, 61] and by 
inducing pro-inflammatory chemokine and cytokine production, such as IFN-γ, 
IL-8 and IL-2 [62].
Chemoattraction of monocytes by HNP has been proven by De Yang et al. 
by analyzing interleukin-8 induced neutrophil-derived T cell attraction. HNP 
selectively attracted CD4+ naïve T cells and cytotoxic CD8+ T cells for an effective 
immune response, but not memory CD4+ T cells [61]. In addition, HNP promotes 
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an antigen-specific immune response by chemoattracting dendritic cells, the most 
potent antigen-presenting cells (APCs). When administered together with antigens, 
HNPs are able to recruit immature dendritic cells and T cells to microbial infection 
sites, leading to maturation of these monocytes responsible in promoting an adap-
tive immunity towards microorganisms [61]. It has also been proven ex vivo that 
human monocyte-derived dendritic cells (moDCs) undergo maturation and differ-
entiation as response to HNPs, but the DC maturation procedure remains unknown 
[56]. This mechanism seems to be HNP dose dependent: high concentrations 
(micromolar range) of HNP are able to directly disrupt cell membranes of micro-
organisms or some tumor cells, through formation of pores in the cell membrane or 
by interacting with negatively charged molecules [61, 63]. Lower concentrations of 
HNP (nanomolar range) are thought to bind specific cell receptors, responsible for 
chemotactic activities and thus resulting in a immunostimulatory effect [56, 61].
Monocyte-derived dendritic cells seem to play an important role in this HNP-
driven immunity: moDCs can internalize and process antigens in their immature 
state, followed by maturation of moDCs by upregulating MHC class II molecules 
that react with naive CD4 and CD8 T cells to induce their activation, leading to 
induction of adaptive immunity [43, 56]. HNPs are thus thought to form a link 
between innate and adaptive immunity, by serving as chemoattractants and 
immune cell activators [37]. It is demonstrated that HNP-driven DC activation leads 
to an increased DC capacity to stimulate T cells, explaining the possible HNP inter-
play in adaptive immunity [61, 64, 65]. Also in an in vitro cancer-related context, 
HNPs have been produced at the tumor site and showed to be chemoattracting for 
moDCs and to promote the production of stimulatory cytokines [65]. In this way, an 
antitumor immune response can be exerted, as an enhanced antigen presentation is 
established by the HNP-driven DC maturation. This shows promising potential for 
the use of HNPs in anticancer therapy [66].
3. Conclusions
During the last decades, it became more clear that antimicrobial peptides 
(AMPs) are not restricted in characteristics as being antibacterial, but that AMPs 
are also serving as a first-line of defense against fungi, viruses, and even tumor 
cells. Furthermore, these small cationic molecules have been shown to exhibit 
potent immune regulatory activities, including chemoattraction, activation and 
differentiation of leukocytes and monocytes to initiate and further enhance adap-
tive immunity. Combined, we believe that AMPs may hold great potential to be 
used as lead for new (co-)therapeutic agents.
With proteomic approaches, more in particular mass spectrometry, it is feasible 
to identify (cyclic) AMPs in their active form after their corresponding proteolysis. 
While emphasis has been put strongly on HNP identification in a tumorimmu-
nology-related context, it is also important to stress out that mass spectrometric 
analyses allows for the detection and identification of native AMPs in different 
specimens, even when present at low concentrations. These unbiased analyses can 
lead to the detection and identification of new AMPs, important for future drug 
development.
In this way, human neutrophil peptide (HNP) 1, 2 and 3 were identified in a 
non-small cell lung cancer (NSCLC) related context, of which the presence have 
been shown to be discriminative between a responding and a nonresponding 
NSCLC patient towards anti-PD-(L)1 immunotherapeutics. Although the biological 
activity of HNPs is well described against bacteria and viruses, little is known about 
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of HNP1-3, while it has also been proven that these HNPs do not show a direct 
cytolytic activity towards NSCLC, but a reduced NSCLC proliferation was observed 
in the presence of HNP and peripheral blood mononuclear cells (PBMC) in vitro. 
In the latter case, increasement of IFN-γ was observed, referring a cell-mediated 
immunity. The question raised by these findings is; what is the mechanism of 
HNP-mediated immunity? Do the HNPs attack the NSCLC cells directly through 
interaction with the negatively charged phosphatidylserine on the outer leaflet of 
the tumor cells? This may result in tumor-associated antigen release responsible 
for activation of a proper immune response. Also, it is increasingly evident that 
these HNPs are responsible for an enhanced antigen-specific immune response by 
activating dendritic cells: upon HNP stimulation, dendritic cells are recruited to 
the tumor site, followed by maturation and differentiation of these dendritic cells, 
leading to an enhanced adaptive immune response. However, the exact HNP-
driven mechanisms are still largely unknown. Further investigation will reveal if 
HNPs could be a promising approach in future anticancer therapeutics, possibly in 
synergy with immunotherapy.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
13
Mass Spectrometry (Imaging) for Detection and Identification of Cyclic AMPs: Focus on Human…
DOI: http://dx.doi.org/10.5772/intechopen.99251
References
[1] Zhang LJ, Gallo RL: Antimicrobial 
peptides. Curr Biol. 2016; 26: R14–R19. 
DOI: 10.1016/j.cub.2015.11.017
[2] Huan Y, Kong Q, Mou H, et al.: 
Antimicrobial Peptides: Classification, 
Design, Application and Research 
Progress in Multiple Fields. Front 
Microbiol. 2020; 11: 1-21. DOI: 10.3389/
fmicb.2020.582779
[3] Brogden KA: Antimicrobial peptides: 
Pore formers or metabolic inhibitors in 
bacteria? Nat Rev Microbiol. 2005; 3: 
238-250. DOI: 10.1038/nrmicro1098
[4] Vale N, Aguiar L, Gomes P: 
Antimicrobial peptides : a new class of 
antimalarial drugs? Front Pharmacol. 
2014; 5: 1-13. DOI: 10.3389/fphar.2014. 
00275
[5] De Cesare GB, Cristy SA, Garsin DA, 
et al.: Antimicrobial peptides: A new 
frontier in antifungal therapy. MBio. 
2020; 11: 1-21. DOI: 10.1128/mBio. 
02123-20
[6] Xia S, Liu M, Wang C, et al.: 
Inhibition of SARS-CoV-2 (previously 
2019-nCoV) infection by a highly potent 
pan-coronavirus fusion inhibitor 
targeting its spike protein that harbors a 
high capacity to mediate membrane 
fusion. Cell Res. 2020; 30: 343-355.  
DOI: 10.1038/s41422-020-0305-x
[7] Belaid A, Aouni M, Khelifa R,  
et al.: In vitro antiviral activity of 
dermaseptins against herpes simplex 
virus type 1. J Med Virol. 2002; 66: 
229-234. DOI: 10.1002/jmv.2134
[8] Edward Robinson W, McDougall B, 
Tran D, et al.: Anti-HIV-1 activity of 
indolicidin, an antimicrobial peptide 
from neutrophils. J Leukoc Biol. 1998; 
63: 94-100. DOI: 10.1002/jlb.63.1.94
[9] Tornesello AL, Borrelli A, 
Buonaguro L, et al.: Antimicrobial 
Peptides as Anticancer Agents: 
Functional Properties and Biological 
Activities. Molecules. 2020; 25: 1-25. 
DOI: 10.3390/molecules25122850
[10] Pasupuleti M, Schmidtchen A, 
Malmsten M, et al.: Antimicrobial 
peptides : key components of the innate 
immune system Antimicrobial peptides : 
key components of the innate immune 
system. Crit Rev Biotechnol. 2012; 32: 
143-171. DOI: 10.3109/07388551.2011. 
594423
[11] Lai Y, Gallo RL: AMPed Up 
immunity: how antimicrobial peptides 
have multiple roles in immune defense. 
Trends Immunol. 2009; 30: 131-141. 
DOI: 10.1016/j.it.2008.12.003.AMPed
[12] Yu J, Mookherjee N, Wee K, et al.: 
Host Defense Peptide LL-37, in Synergy 
with Inflammatory Mediator IL-1β, 
Augments Immune Responses by 
Multiple Pathways. J Immunol. 2007; 
179: 7684-7691. DOI: 10.4049/
jimmunol.179.11.7684
[13] Scheenstra MR, van Harten RM, 
Veldhuizen EJA, et al.: Cathelicidins 
Modulate TLR-Activation and 
Inflammation. Front Immunol. 2020; 11: 
1-16. DOI: 10.3389/fimmu.2020.01137
[14] Kang HK, Kim C, Seo CH, et al.: The 
therapeutic applications of 
antimicrobial peptides (AMPs): a patent 
review. J Microbiol. 2017; 55: 1-12.  
DOI: 10.1007/s12275-017-6452-1
[15] Seo MD, Won HS, Kim JH, et al.: 
Antimicrobial peptides for therapeutic 
applications: A review. Molecules. 2012; 
17: 12276-12286. DOI: 10.3390/
molecules171012276
[16] Yu Y, Cooper CL, Wang G, et al.: 
Engineered Human Cathelicidin 
Antimicrobial Peptides Inhibit Ebola 




[17] Berghmans E. Mass spectrometry 
imaging combined with top-down 
proteomics to predict a more accurate 
immunotherapy response in non-small 
cell lung cancer patients [thesis]. 
Antwerpen: Universiteit Antwerpen; 
2020.
[18] Cole SR, Ma X, Zhang X, et al.: 
Electron Transfer Dissociation (ETD) of 
peptides containing intrachain disulfide 
bonds. J Am Soc Mass Spectrom. 2012; 
23: 310-320. DOI: 10.1007/s13361-011- 
0300-z
[19] Wu S-L, Jiang H, Lu Q, et al.: Mass 
Spectrometric Determination of 
Disulfide Linkages in Recombinant 
Therapeutic Proteins Using On-line 
LC-MS with Electron Transfer 
Dissociation (ETD). Anal Chem. 2009; 
81: 112-122. DOI: 10.1007/s10439-011-
0452-9.Engineering
[20] Compton PD, Strukl J V., Bai DL,  
et al.: Optimization of electron transfer 
dissociation via informed selection of 
reagents and operating parameters. Anal 
Chem. 2012; 84: 1781-1785. DOI: 
10.1021/ac202807h
[21] Berghmans E, Jacobs J, Deben C,  
et al.: Mass Spectrometry Imaging 
Reveals Neutrophil Defensins as 
Additional Biomarkers for Anti-
PD-(L)1 Immunotherapy Response in 
NSCLC Patients. Cancers (Basel). 2020; 
12: 863. DOI: 10.3390/cancers12040863
[22] Ahmed A, Siman-Tov G, Hall G,  
et al.: Human antimicrobial peptides as 
therapeutics for viral infections. 
Viruses. 2019; 11: 1-26. DOI: 10.3390/
v11080704
[23] Azkargorta M, Soria J, Ojeda C,  
et al.: Human basal tear peptidome 
characterization by CID, HCD, and ETD 
followed by in silico and in vitro 
analyses for antimicrobial peptide 
identification. J Proteome Res. 2015; 14: 
2649-2658. DOI: 10.1021/acs.jproteome. 
5b00179
[24] Chughtai K, Heeren RMA: Mass 
Spectrometric Imaging for Biomedical 
Tissue Analysis - Chemical Reviews 
(ACS Publications). Chem Rev. 2011; 
110: 3237-3277. DOI: 10.1021/cr100012c. 
Mass
[25] Minerva L, Clerens S, Baggerman G, 
et al.: Direct profiling and identification 
of peptide expression differences in the 
pancreas of control and ob/ob mice by 
imaging mass spectrometry. Proteomics. 
2008; 8: 3763-3774. DOI: 10.1002/
pmic.200800237
[26] Ahlf Wheatcraft DR, Liu X, 
Hummon AB: Sample Preparation 
Strategies for Mass Spectrometry 
Imaging of 3D Cell Culture Models. J Vis 
Exp. 2014; 1-7. DOI: 10.3791/52313
[27] Berghmans E, Boonen K, Maes E,  
et al.: Implementation of Maldi mass 
spectrometry imaging in cancer 
proteomics research: Applications and 
challenges. J Pers Med. 2020; 10: 1-12. 
DOI: 10.3390/jpm10020054
[28] Stegemann C, Hoffmann R: 
Sequence Analysis of Antimicrobial 
Peptides by Tandem Mass Spectrometry. 
Methods Mol Biol.; 494. DOI: 
10.1007/978-1-59745-419-3
[29] Cerrato A, Capriotti AL, Capuano F, 
et al.: Identification and Antimicrobial 
Activity of Medium-Sized and Short 
Peptides from Yellowfin Tuna (Thunnus 
albacares) Simulated Gastrointestinal 
Digestion. Foods.; 9
[30] Cunsolo V, Schicchi R, 
Chiaramonte M, et al.: Identification of 
New Antimicrobial Peptides from 
Mediterranean Medical Plant Charybdis 
pancration (Steinh.) Speta. Antibiotics. 
2020; 9: 1-13
[31] Berghmans E, Van Raemdonck G, 
Schildermans K, et al.: MALDI Mass 
Spectrometry Imaging Linked with 
Top-Down Proteomics as a Tool to Study 
the Non-Small-Cell Lung Cancer Tumor 
15
Mass Spectrometry (Imaging) for Detection and Identification of Cyclic AMPs: Focus on Human…
DOI: http://dx.doi.org/10.5772/intechopen.99251
Microenvironment. Methods Protoc. 
2019; 2: 1-21. DOI: 10.3390/mps2020 
044
[32] Sasaki K, Osaki T, Minamino N: 
Large-scale identification of 
endogenous secretory peptides using 
electron transfer dissociation mass 
spectrometry. Mol Cell Proteomics. 
2013; 12: 700-709. DOI: 10.1074/mcp.
M112.017400
[33] Andersson DI, Hughes D, Kubicek-
Sutherland JZ: Mechanisms and 
consequences of bacterial resistance to 
antimicrobial peptides. Drug Resist 
Updat. 2016; 26: 43-57. DOI: 10.1016/j.
drup.2016.04.002
[34] Ehmann D, Wendler J, Koeninger L, 
et al.: Paneth cell α-defensins HD-5 and 
HD-6 display differential degradation 
into active antimicrobial fragments. 
Proc Natl Acad Sci U S A. 2019; 116: 
3746-3751. DOI: 10.1073/pnas.18173 
76116
[35] Shimizu Y, Nakamura K, Yoshii A,  
et al.: Paneth cell α-defensin misfolding 
correlates with dysbiosis and ileitis in 
Crohn’s disease model mice. Life Sci 
Alliance. 2020; 3: 1-15. DOI: 10.26508/
LSA.201900592
[36] Szyk A, Wu Z, Tucker K, et al.: 
Crystal structures of human α-defensins 
HNP4, HD5, and HD6. Protein Sci. 
2006; 15: 2749-2760. DOI: 10.1110/
ps.062336606
[37] Droin N, Hendra JB, Ducoroy P,  
et al.: Human defensins as cancer 
biomarkers and antitumour molecules. J 
Proteomics. 2009; 72: 918-927. DOI: 
10.1016/j.jprot.2009.01.002
[38] Beckloff N, Diamond G: 
Computational Analysis Suggests 
Beta-Defensins Are Processed to Mature 
Peptides By Signal Peptidase. Protein 
Pept Lett. 2008; 15: 536-540.  
DOI: 10.2174/092986608784567618
[39] Luthfi M, Setijanto D, Rahardjo MB, 
et al.: Correlation between human 
neutrophil peptide 1-3 secretion and 
azurophilic granule (CD63) expression 
in early childhood caries. 2019; 16: 
81-86. DOI: 10.4103/1735-3327.250973
[40] Amerikova M, Pencheva El-Tibi I, 
Maslarska V, et al.: Antimicrobial 
activity, mechanism of action, and 
methods for stabilisation of defensins as 
new therapeutic agents. Biotechnol 
Biotechnol Equip. 2019; 33: 671-682. 
DOI: 10.1080/13102818.2019.1611385
[41] Khusro A, Aarti C, Agastian P: 
Anti-tubercular peptides: A quest of 
future therapeutic weapon to combat 
tuberculosis. Asian Pac J Trop Med. 
2016; 9: 1023-1034. DOI: 10.1016/j.
apjtm.2016.09.005
[42] Bolatchiev A: Antibacterial activity 
of human defensins against 
Staphylococcus aureus and Escherichia 
coli. PeerJ.; 8. DOI: 10.7717/peerj.10455
[43] Rodríguez-García M, Climent N, 
Oliva H, et al.: Increased α-defensins 1-3 
production by dendritic cells in HIV-
infected individuals is associated with 
slower disease progression. PLoS One. 
2010; 5: e9436. DOI: 10.1371/journal.
pone.0009436
[44] Buck CB, Day PM, Thompson CD, 
et al.: Human α-defensins block 
papillomavirus infection. Proc Natl 
Acad Sci U S A. 2006; 103: 1516-1521. 
DOI: 10.1073/pnas.0508033103
[45] Salvatore M, Garcı A, Ruchala P,  
et al.: a-Defensin Inhibits Influenza 
Virus Replication by Cell-Mediated 
Mechanism(s). 2007; 100129: 835-843. 
DOI: 10.1086/521027
[46] Hsieh I, Hartshorn KL: The Role of 
Antimicrobial Peptides in Influenza 
Virus Infection and Their Potential as 
Antiviral and Immunomodulatory 




[47] Ferdowsi S, Pourfathollah AA, 
Amiri F, et al.: Evaluation of anticancer 
activity of α-defensins purified from 
neutrophils trapped in leukoreduction 
filters. Life Sci. 2019; 224: 249-254. DOI: 
10.1016/j.lfs.2019.03.072
[48] Gaspar D, Freire JM, Pacheco TR, et 
al.: Apoptotic human neutrophil 
peptide-1 anti-tumor activity revealed 
by cellular biomechanics. Biochim 
Biophys Acta - Mol Cell Res. 2015; 1853: 
308-316. DOI: 10.1016/j.bbamcr.2014. 
11.006
[49] Müller CA, Markovic-Lipkovski J, 
Klatt T, et al.: Human α-Defensins 
HNPs-1, −2, and −3 in Renal Cell 
Carcinoma. Am J Pathol. 2002; 160: 
1311-1324. DOI: 10.1016/S0002-9440 
(10)62558-8
[50] Bateman A, Singh A, Jothy S, et al.: 
The levels and biologic action of the 
human neutrophil granule peptide HP-1 
in lung tumors. Peptides. 1992; 13: 
133-139. DOI: 10.1016/0196-9781 
(92)90152-S
[51] Mothes H, Melle C, Ernst G, et al.: 
Human Neutrophil Peptides 1-3 - Early 
markers in development of colorectal 
adenomas and carcinomas. Dis Markers. 
2008; 25: 123-129. DOI: 10.1155/ 
2008/693937
[52] Parvy J-P, Yu Y, Dostalova A, et al.: 
The antimicrobial peptide defensin 
cooperates with tumour necrosis factor 
to drive tumour cell death in Drosophila. 
Elife. 2019; 8: 1-26. DOI: 10.7554/
elife.45061
[53] Cory S: Phosphatidylserine hide-
and-seek. Proc Natl Acad Sci U S A. 
2018; 115: 12092-12094. DOI: 10.1073/
pnas.1817485115
[54] Sharma B, Kanwar SS: 
Phosphatidylserine: A cancer cell 
targeting biomarker. Semin Cancer Biol. 
2018; 52: 17-25. DOI: 10.1016/j.
semcancer.2017.08.012
[55] Nguyen VP, Dixson AC, Barrera FN: 
The effect of phosphatidylserine on the 
membrane insertion of the cancer-
targeting ATRAM peptide is defined by 
the non-inserting end. BioRxiv. 2019; 1: 
1-13. DOI: 10.1017/CBO978110741 
5324.004
[56] Rodríguez-garcía M, Oliva H, 
Climent N, et al.: Impact of α - 
defensins1 – 3 on the maturation and 
differentiation of human monocyte-
derived DCs . Concentration-dependent 
opposite dual effects. Clin Immunol. 
2009; 131: 374-384. DOI: 10.1016/j.
clim.2009.01.012
[57] Huang HW, Charron NE: 
Understanding membrane-active 
antimicrobial peptides. Q Rev Biophys. 
2017; 50: 1-17. DOI: 10.1017/
S0033583517000087
[58] Riedl S, Rinner B, Asslaber M,  
et al.: In search of a novel target - 
Phosphatidylserine exposed by non-
apoptotic tumor cells and metastases of 
malignancies with poor treatment 
efficacy. Biochim Biophys Acta - 
Biomembr. 2011; 1808: 2638-2645.  
DOI: 10.1016/j.bbamem.2011.07.026
[59] Rousseau A, McEwen AG, 
Poussin-Courmontagne P, et al.: TRAF4 
Is a Novel Phosphoinositide-Binding 
Protein Modulating Tight Junctions and 
Favoring Cell Migration. PLoS Biol.; 11. 
DOI: 10.1371/journal.pbio.1001726
[60] Granot Z: Neutrophils as a 
Therapeutic Target in Cancer. Front 
Immunol. 2019; 10: 1710. DOI: 10.3389/
fimmu.2019.01710
[61] Yang D, Chen Q, Chertov O, et al.: 
Human neutrophil defensins selectively 
chemoattract naive T and immature 
dendritic cells brane of microbes. J 
Leukoc Biol. 2000; 68: 9-14.  
DOI: 10.1189/jlb.68.1.9
[62] Vaschetto R, Grinstein J, Del 
Sorbo L, et al.: Role of human 
17
Mass Spectrometry (Imaging) for Detection and Identification of Cyclic AMPs: Focus on Human…
DOI: http://dx.doi.org/10.5772/intechopen.99251
neutrophil peptides in the initial 
interaction between lung epithelial cells 
and CD4 + lymphocytes. J Leukoc Biol. 
2007; 81: 1022-1031. DOI: 10.1189/
jlb.0706435
[63] Ganz T: The Role of Antimicrobial 
Peptides in Innate Immunity. Integr 
Comp Biol. 2003; 43: 300-304. DOI: 
10.1093/icb/43.2.300
[64] Rodríguez-García M, Oliva H, 
Climent N, et al.: Human immature 
monocyte-derived dendritic cells 
produce and secrete α-defensins 1-3. J 
Leukoc Biol. 2007; 82: 1143-1146.  
DOI: 10.1189/jlb.0507295
[65] Presicce P, Giannelli S, Taddeo A,  
et al.: Human defensins activate 
monocyte-derived dendritic cells, 
promote the production of 
proinflammatory cytokines, and 
up-regulate the surface expression of 
CD91. J Leukoc Biol. 2009; 86: 941-948. 
DOI: 10.1189/jlb.0708412
[66] Wang Y, Li D, Shi H, et al.: 
Intratumoral Expression of Mature 
Human Neutrophil Peptide-1 Mediates 
Antitumor Immunity in Mice. 2009; 15: 
6901-6912. DOI: 10.1158/1078-0432.
CCR-09-0484
